Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Preclinical evidence for employing MEK inhibition in NRAS mutated pediatric gastroenteropancreatic neuroendocrine-like tumors

Translational Oncology(2024)10.1016/j.tranon.2024.102045Source: DataRank Database

Preclinical evidence for employing MEK inhibition in NRAS mutated pediatric gastroenteropancreatic neuroendocrine-like tumors is a research paper published in Translational Oncology (2024). On theSindex it has a DataRank of 0. It has been cited 1 time.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access1 citations

Download PDF

Cite:

Linked data & code

geo

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)OA: goldTopics (6)IDs (PubMed, PMC)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Andee M. Beierle,Adele P. Williams,Raoud Marayati ORCID,Laura V. Bownes,Hooper R Market

Live enrichment

PubMed:38959709 PMC:PMC11269785

National Institutes of Health

Grant: T32CA183926

National Institutes of Health

Grant: 5T32GM008361

National Institutes of Health

Grant: P30 CA013148

National Institutes of Health

Grant: T32 CA229102

National Institutes of Health

Grant: P30 AR048311

National Institutes of Health

Grant: P30 AI27667

National Institutes of Health

Grant: U01 CA223976

goldLicense: cc-by-nc-nd

publisherhttps://doi.org/10.1016/j.tranon.2024.102045

publisherhttps://api.elsevier.com/content/article/PII:S1936523324001724?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1936523324001724?httpAccept=text/plain

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11269785/pdf/main.pdf

repositoryhttps://doaj.org/article/0515712cdd0f4633a52a9cf06e81c2dc

Keywords

Metastatic DiseasePediatric CancerTarget TherapiesPatient-derived XenograftsMek InhibitionNras Mutation

Preclinical evidence for employing MEK inhibition in NRAS mutated pediatric gastroenteropancreatic neuroendocrine-like tumors

FAIR Checklist

Authors (12)

Funding (7 grants)

Open Access

Topics

Annotations (Europe PMC)